Premium
Antibody‐drug therapeutic conjugates: Potential of antibody‐siRNAs in cancer therapy
Author(s) -
Yarian Fatemeh,
Alibakhshi Abbas,
Eyvazi Shirin,
Arezumand Roghaye,
Ahangarzadeh Shahrzad
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.28490
Subject(s) - small interfering rna , drug , antibody drug conjugate , conjugate , antibody , monoclonal antibody , drug delivery , targeted drug delivery , therapeutic index , cancer research , drug carrier , pharmacology , medicine , chemistry , rna , immunology , biochemistry , mathematical analysis , mathematics , organic chemistry , gene
Codelivery is a promising strategy of targeted delivery of cytotoxic drugs for eradicating tumor cells. This rapidly growing method of drug delivery uses a conjugate containing drug linked to a smart carrier. Both two parts usually have therapeutic properties on the tumor cells. Monoclonal antibodies and their derivatives, such as Fab, scFv, and bsAb due to targeting high potent have now been attractive candidates as drug targeting carrier systems. The success of some therapeutic agents like small interfering RNA (siRNA), a small noncoding RNAs, with having problems such as enzymatic degradation and rapid renal filtration need to an appropriate carrier. Therefore, the aim of this study is to review the recent enhancements in development of antibody drug conjugates (ADCs), especially antibody–siRNA conjugates (SRCs), its characterizations and mechanisms in innovative cancer therapy approaches.